Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11:69
Article PubMed PubMed Central Google Scholar
Silveira CRF, Corveloni AC, Caruso SR, Macêdo NA, Brussolo NM, Haddad F et al (2022) Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol 13:947648
Article CAS PubMed PubMed Central Google Scholar
Li W, Wu L, Huang C, Liu R, Li Z, Liu L et al (2020) Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review. Ann Transl Med 8:1093
Article CAS PubMed PubMed Central Google Scholar
Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N (2020) Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther 27:799–809
Article CAS PubMed Google Scholar
Abranches E, Spyrou S, Ludwig T (2020) GMP Banking of Human Pluripotent Stem Cells: a US and UK perspective. Stem Cell Res 45:101805
Article CAS PubMed Google Scholar
Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S et al (2023) Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv 7:541–548
Article CAS PubMed Google Scholar
Ying Z, He T, Wang X, Zheng W, Lin N, Tu M et al (2021) Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. BMC Cancer 21:198
Article CAS PubMed PubMed Central Google Scholar
Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B (2022) Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer 10. https://doi.org/10.1136/jitc-2022-005678
Campbell A, Brieva T, Raviv L, Rowley J, Niss K, Brandwein H et al (2015) Concise review: process development considerations for cell therapy. Stem Cells Transl Med 4:1155–1163
Article PubMed PubMed Central Google Scholar
Scott M, Clarke D, Lipsitz Y, Brandwein H, Allickson J, Alzebdeh D et al (2020) Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies. Cytotherapy 22:669–676
Article CAS PubMed Google Scholar
FDA. Considerations for the development of chimeric antigen receptor (CAR) T cell products: Guidance for Industry (2024) Available: https://www.fda.gov/media/156896/download
Wang X, Rivière I (2015) Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther 22:85–94
Article CAS PubMed PubMed Central Google Scholar
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P et al (2021) Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov 2:408–422
Article CAS PubMed PubMed Central Google Scholar
Wang X, Rivière I (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015
Article CAS PubMed PubMed Central Google Scholar
Ittershagen S, Ericson S, Eldjerou L, Shojaee A, Bleickardt E, Patel M et al (2019) Industry’s Giant Leap into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) immunotherapy. Curr Hematol Malig Rep 14:47–55
Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D (2023) Systematic review on CAR-T cell clinical trials up to 2022: Academic Center Input. Cancers 15. https://doi.org/10.3390/cancers15041003
Silva DN, Chrobok M, Ahlén G, Blomberg P, Sällberg M, Pasetto A (2022) ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing. Immunooncol Technol 16:100099
Article CAS PubMed PubMed Central Google Scholar
Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY (2024) CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med 221. https://doi.org/10.1084/jem.20230903
Baguet C, Larghero J, Mebarki M (2024) Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies. Blood Adv 8:337–342
Article CAS PubMed Google Scholar
Elsallab M, Maus MV (2023) Expanding access to CAR T cell therapies through local manufacturing. Nat Biotechnol. https://doi.org/10.1038/s41587-023-01981-8
Tyagarajan S, Schmitt D, Acker C, Rutjens E (2019) Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture. Cytotherapy 21:1198–1205
Article CAS PubMed Google Scholar
Qayed M, McGuirk JP, Myers GD, Parameswaran V, Waller EK, Holman P et al (2022) Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy 24:869–878
Article CAS PubMed Google Scholar
Burke CJ, Zylberberg C (2019) Sources of variability in Manufacturing of cell therapeutics. Regenerative Eng Translational Med 5:332–340
Dreyzin A, Panch SR, Shalabi H, Yates B, Highfill SL, Jin P et al (2023) Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. Mol Ther Methods Clin Dev 28:51–61
Article CAS PubMed Google Scholar
Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P et al (2019) Effect of cryopreservation on autologous chimeric Antigen receptor T cell characteristics. Mol Ther 27:1275–1285
Article CAS PubMed PubMed Central Google Scholar
Xu H, Cao W, Huang L, Xiao M, Cao Y, Zhao L et al (2018) Effects of cryopreservation on chimeric antigen receptor T cell functions. Cryobiology 83:40–47
Article CAS PubMed Google Scholar
Brezinger-Dayan K, Itzhaki O, Melnichenko J, Kubi A, Zeltzer L-A, Jacoby E et al (2022) Impact of cryopreservation on CAR T production and clinical response. Front Oncol 12:1024362
Article CAS PubMed PubMed Central Google Scholar
Meneghel J, Kilbride P, Morris GJ (2020) Cryopreservation as a key element in the successful delivery of cell-based Therapies-A Review. Front Med 7:592242
Satwani P, Chao K, Lopez-Garcia M, Hall M, Jin Z, Winestone LE et al (2023) Establishing costs for commercial chimeric Antigen receptor T-Cell (Tisagenlecleucel; Kymriah) in children and young adult B-Cell Acute Lymphoblastic Leukemia; a merged analysis from the Prwcc and PHIS. Blood 142:6912–6912
Ten Ham RMT, Hövels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH et al (2020) What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy 22:388–397
Tice JA, Judith ME, Walsh I, Otuonye R, Chapman V, Kumar M, Seidner DA, Ollendorf SD, Pearson MD, Whittington JD, Campbell R. Brett McQueen,Chong Kim, Mausam Patidarm Samuel McGuffin. Chimeric Antigen Receptor T-Cell Therapy for BCell Cancers: Effectiveness and Value. Available: https://icer.org/wp-content/uploads/2020/10/ICER_CAR_T_Final_Evidence_Report_032318.pdf
Jørgensen J, Kefalas P (2021) The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med 16:405–422
Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM et al (2023) Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv 7:801–810
Article CAS PubMed Google Scholar
Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M (2022) Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or later therapy in relapsed or refractory diffuse large B-Cell lymphoma. JAMA Netw Open 5:e2245956
留言 (0)